Last reviewed · How we verify

NCT03680794

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

Status unknown NA Last updated 20 October 2022
What this trial tests

NA trial testing sampling of ophthalmic liquid in Diabetic Retinopathy in 120 participants. Status unknown.

Timeline
27 June 2018
Primary endpoint
1 December 2024
1 February 2025

Quick facts

Lead sponsorCHU de Reims
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment120
Start date27 June 2018
Primary completion1 December 2024
Estimated completion1 February 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

CHU de Reims — full company profile →

Who can join

18 and older, any sex, with Diabetic Retinopathy or Retinal Vein Occlusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test. The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Retinopathy

Currently open trials in the same condition.

Other CHU de Reims trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03680794.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing